Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

      Cardinal Health Logo (PRNewsfoto/Cardinal Health)

      News provided by

      Cardinal Health, Inc.

      Feb 05, 2026, 06:45 ET

      Share this article

      Share this article


      • Revenue increased 19% to $65.6 billion
      • GAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97
      • Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63
      • Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35
      • Cardinal Health completes annual baseline share repurchase of $750 million
      • Cardinal Health reaches targeted leverage range3

      DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29% to $707 million and GAAP diluted earnings per share (EPS) increased 19% to $1.97. Second quarter non-GAAP operating earnings increased 38% to $877 million. Non-GAAP diluted EPS increased 36% to $2.63, reflecting the increase in non-GAAP operating earnings and a lower share count, partially offset by an increase in interest and other expense due to financing costs related to previously announced acquisitions.

      "Our strong second-quarter performance reflects at least double-digit segment profit growth across all five of our operating segments," said Jason Hollar, CEO of Cardinal Health. "Our ongoing momentum and the team's consistent execution against our strategic priorities gives us confidence to raise our fiscal 2026 outlook."

      Q2 FY26 summary


      Q2 FY26


      Q2 FY25


      Y/Y

      Revenue

      $65.6 billion


      $55.3 billion


      19 %

      Operating earnings

      $707 million


      $549 million


      29 %

      Non-GAAP operating earnings

      $877 million


      $635 million


      38 %

      Net earnings attributable to Cardinal Health, Inc.

      $467 million


      $400 million


      17 %

      Non-GAAP net earnings attributable to Cardinal Health, Inc.

      $624 million


      $468 million


      33 %

      Effective Tax Rate

      25.2 %


      21.4 %



      Non-GAAP Effective Tax Rate

      21.4 %


      21.4 %



      Diluted EPS attributable to Cardinal Health, Inc.

      $1.97


      $1.65


      19 %

      Non-GAAP diluted EPS attributable to Cardinal Health, Inc.

      $2.63


      $1.93


      36 %

      Segment results

      Pharmaceutical and Specialty Solutions segment


      Q2 FY26


      Q2 FY25


      Y/Y

      Revenue

      $              60.7  billion


      $             50.8 billion


      19 %

      Segment profit

      $               687 million


      $              531 million


      29 %

      Second quarter revenue for the Pharmaceutical and Specialty Solutions segment increased 19% to $60.7 billion, driven by brand and specialty pharmaceutical sales growth from existing and new customers.

      Pharmaceutical and Specialty Solutions segment profit increased 29% to $687 million in the second quarter, driven by contributions from brand and specialty products, the acquisition of MSO platforms and positive generics program performance.

      Global Medical Products and Distribution segment


      Q2 FY26


      Q2 FY25


      Y/Y

      Revenue

      $               3.3  billion


      $                3.2  billion


      3 %

      Segment profit

      $               37 million


      $                 18 million


      106 %

      Second quarter revenue for the Global Medical Products and Distribution segment increased 3% to $3.3 billion, driven by volume growth from existing customers.

      Global Medical Products and Distribution segment profit increased 106% to $37 million in the second quarter, driven by growth from existing customers and the beneficial net impact of cost optimization initiatives, partially offset by an adverse net impact of tariffs.

      Other4


      Q2 FY26


      Q2 FY25


      Y/Y

      Revenue

      $               1.7  billion


      $                1.3  billion


      34 %

      Segment profit

      $              179 million


      $               118 million


      52 %

      Second quarter revenue for Other increased 34% to $1.7 billion, driven by growth across the three operating segments: at-Home Solutions (including the acquisition of Advanced Diabetes Supply), Nuclear and Precision Health Solutions and OptiFreight Logistics.

      Other segment profit increased 52% to $179 million in the second quarter, driven by growth across the three operating segments: at-Home Solutions (including the acquisition of Advanced Diabetes Supply), OptiFreight Logistics and Nuclear and Precision Health Solutions.

      Fiscal year 2026 outlook2

      Cardinal Health is raising its fiscal year 2026 guidance for non-GAAP diluted EPS attributable to Cardinal Health, Inc. to a range of $10.15 to $10.35 (+23% to +26% growth). This updated guidance reflects:

      • Pharmaceutical and Specialty Solutions segment profit growth raised and narrowed to 20% to 22%, from the prior range of 16% to 19%
      • Global Medical Products and Distribution segment profit raised to approximately $150 million, from the prior guidance of at least $140 million
      • Other segment profit growth raised to 33% to 35%, from the prior range of 29% to 31%
      • Non-GAAP effective tax rate decreased to a range of 21% to 23%, from the prior range of 22% to 24%
      • Diluted weighted average shares outstanding decreased to a range of 237 million to 238 million, from the prior outlook of ~238 million

      Recent highlights

      • Cardinal Health completed an additional $375 million accelerated share repurchase program in the second quarter, bringing year-to-date share repurchases in fiscal year 2026 to $750 million.
      • Cardinal Health's The Specialty Alliance leading multi-specialty MSO platform completed the acquisition of Solaris Health, the country's leading Urology MSO with over 750 providers, on November 3rd.
      • Cardinal Health's direct-to-patient at-Home Solutions business recently introduced the ContinuCare™ Pathway program, which leverages the full Cardinal Health portfolio to simplify diabetes supply management for partner pharmacies and patients, and announced a key partnership with Publix Super Markets Inc.
      • Reinforcing its commitment to a world-class culture, Cardinal Health earned Great Place to Work Certification in six countries, including the U.S.

      Webcast
      Cardinal Health will host a webcast today at 8:30 a.m. ET to discuss second quarter results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required.

      Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.

      About Cardinal Health
      Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom.

      Contacts
      Media: Erich Timmerman, [email protected] and 614.757.8231
      Investors: Matt Sims, [email protected] and 614.553.3661

      1GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP. See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.
      2The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation.
      3The company maintains a targeted leverage range of 2.75x to 3.25x Adjusted Debt to EBITDA as defined by Moody's Ratings. The company achieved 3.2x leverage as of December 31, 2025 per internal estimates.
      4Other includes the following three operating segments: Nuclear and Precision Health Solutions (NPHS), at-Home Solutions and OptiFreight Logistics, which are not significant enough individually to require reportable segment disclosure.

      Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive email alerts when the company posts news releases, SEC filings and certain other information on its website.

      Cautions Concerning Forward-Looking Statements
      This release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include our ability to  manage uncertainties associated with the pricing of branded pharmaceuticals and to navigate uncertainties arising from proposed or final regulatory changes, including those related to pharmaceutical pricing and tariffs the risk that we may fail to achieve our strategic objectives, including the ongoing integration of recent acquisitions and the continued execution of the GMPD Improvement Plan initiatives; competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases made under their contracts with us or terminate or not renew their contracts, whether due to price increases or otherwise; risks associated with litigation matters, including Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act; the risk that events outside of our control, such as weather or geopolitical events, may impact demand for our products or may cause supply delays or shortages that impact our cost and ability to fulfill customer demand; and the performance of our generics program, including the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture or other components of our generics programs. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8K reports and exhibits to those reports. This release reflects management's views as of February 5, 2026. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this report can or will be achieved or completed. Cardinal Health provides definitions and reconciliations of non-GAAP financial measures and their most directly comparable GAAP financial measures at ir.cardinalhealth.com

      Schedule 1


      Cardinal Health, Inc. and Subsidiaries 

      Condensed Consolidated Statements of Earnings (Unaudited)



      Second  Quarter


      Year-to-Date

      (in millions, except per common share amounts)

      2026


      2025


      % Change


      2026


      2025


      % Change

      Revenue

      $        65,627


      $        55,264


      19 %


      $       129,636


      $       107,541


      21 %

      Cost of products sold

      63,230


      53,323


      19 %


      124,920


      103,698


      20 %

      Gross margin

      2,397


      1,941


      23 %


      4,716


      3,843


      23 %













      Operating expenses:












      Distribution, selling, general and administrative expenses

      1,504


      1,306


      15 %


      2,965


      2,583


      15 %

      Restructuring and employee severance

      21


      9




      41


      33



      Amortization and other acquisition-related costs

      130


      105




      234


      179



      Acquisition-related cash and share-based compensation costs

      67


      —




      131


      —



      Impairments and (gain)/loss on disposal of assets, net

      (14)


      3




      (12)


      2



      Litigation (recoveries)/charges, net

      (18)


      (31)




      (18)


      (71)



      Operating earnings

      707


      549


      29 %


      1,375


      1,117


      23 %













      Other (income)/expense, net

      (11)


      3




      (21)


      (2)



      Interest expense, net

      88


      35


      N.M.


      168


      67


      N.M.

      Earnings before income taxes

      630


      511


      23 %


      1,228


      1,052


      17 %













      Provision for income taxes

      159


      110


      45 %


      303


      234


      29 %

      Net earnings

      471


      401


      17 %


      925


      818


      13 %













      Less: Net earnings attributable to noncontrolling interests

      (4)


      (1)




      (8)


      (2)



      Net earnings attributable to Cardinal Health, Inc.

      $            467


      $            400


      17 %


      $            917


      $            816


      12 %













      Earnings per common share attributable to Cardinal Health, Inc.:












      Basic

      $           1.98


      $           1.65


      20 %


      $           3.87


      $           3.37


      15 %

      Diluted

      1.97


      1.65


      19 %


      3.85


      3.35


      15 %













      Weighted-average number of common shares outstanding:












      Basic

      236


      242




      237


      242



      Diluted

      237


      243




      238


      243



      Schedule 2


      Cardinal Health, Inc. and Subsidiaries

      Condensed Consolidated Balance Sheets


      (in millions)

      December 31,
      2025


      June 30, 2025

      Assets

      (Unaudited)



      Current assets:




      Cash and equivalents

      $               2,777


      $               3,874

      Trade receivables, net

      13,662


      13,242

      Inventories, net

      20,116


      16,831

      Prepaid expenses and other

      2,675


      2,414

      Assets held for sale

      —


      12

      Total current assets

      39,230


      36,373





      Property and equipment, net

      2,877


      2,858

      Goodwill and other intangibles, net

      13,978


      12,177

      Other assets

      1,998


      1,714

      Total assets

      $              58,083


      $              53,122





      Liabilities and Shareholders' Deficit




      Current liabilities:




      Accounts payable

      $              38,996


      $              34,713

      Current portion of long-term obligations and other short-term borrowings

      680


      550

      Other accrued liabilities

      3,638


      3,634

      Total current liabilities

      43,314


      38,897





      Long-term obligations, less current portion

      8,347


      7,977

      Deferred income taxes and other liabilities

      9,122


      8,882





      Total shareholders' deficit

      (2,700)


      (2,634)

      Total liabilities and shareholders' deficit

      $              58,083


      $              53,122

      Schedule 3


      Cardinal Health, Inc. and Subsidiaries

      Consolidated Statements of Cash Flows (Unaudited)



      Second  Quarter


      Year-to-Date

      (in millions)

      2026


      2025


      2026


      2025

      Cash flows from operating activities:








      Net earnings

      $                471


      $                401


      $                925


      $                818









      Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:








      Depreciation and amortization

      234


      192


      467


      374

      Impairments and loss on sale of other investments

      —


      1


      5


      2

      Impairments and (gain)/loss on disposal of assets, net

      (14)


      3


      (12)


      2

      Share-based compensation

      87


      30


      180


      60

      Provision for bad debts

      14


      12


      27


      28

      Change in operating assets and liabilities, net of effects from acquisitions and divestitures:








        (Increase)/decrease in trade receivables

      341


      (541)


      (198)


      (253)

        Increase in inventories

      (2,543)


      (1,289)


      (3,279)


      (1,967)

        Increase/(decrease) in accounts payable

      2,029


      924


      4,176


      (470)

        Repurchases of liability-classified Specialty Alliance Units

      (6)


      —


      (22)


      —

        Other accrued liabilities and operating items, net

      73


      (129)


      (610)


      (637)

      Net cash provided by/(used in) operating activities

      686


      (396)


      1,659


      (2,043)









      Cash flows from investing activities:








      Acquisition of subsidiaries, net of cash acquired

      (1,884)


      (1,076)


      (1,925)


      (1,076)

      Additions to property and equipment

      (131)


      (99)


      (239)


      (189)

      Proceeds from the disposal of property and equipment

      31


      —


      31


      —

      Proceeds from short-term investment in time deposit

      —


      200


      —


      200

      Other investing items, net

      4


      (1)


      11


      1

      Net cash used in investing activities

      (1,980)


      (976)


      (2,122)


      (1,064)









      Cash flows from financing activities:








      Proceeds from long-term obligations, net of issuance costs

      —


      2,869


      989


      2,869

      Reduction of long-term obligations

      (12)


      (414)


      (524)


      (423)

      Payments of noncontrolling interests, net

      (1)


      (4)


      (4)


      (4)

      Net tax proceeds/(withholding) from share-based compensation

      (1)


      13


      (81)


      (15)

      Dividends on common shares

      (122)


      (122)


      (251)


      (250)

      Purchase of treasury shares, net

      (383)


      (15)


      (758)


      (390)

      Net cash provided by/(used in) financing activities

      (519)


      2,327


      (629)


      1,787









      Effect of exchange rate changes on cash and equivalents

      (3)


      (12)


      (5)


      (3)









      Net increase/(decrease) in cash and equivalents

      (1,816)


      943


      (1,097)


      (1,323)

      Cash and equivalents at beginning of period

      4,593


      2,867


      3,874


      5,133

      Cash and equivalents at end of period

      $           2,777


      $           3,810


      $           2,777


      $           3,810

      Schedule 4


      Cardinal Health, Inc. and Subsidiaries

      Segment Information



      Second Quarter














      Pharmaceutical and Specialty Solutions


      Global Medical Products and Distribution


      Other

      (in millions)

      2026


      2025


      2026


      2025


      2026


      2025

      Revenue












      Amount

      $             60,669


      $             50,849


      $               3,259


      $               3,154


      $               1,724


      $               1,283

      Growth rate

      19 %


      (4) %


      3 %


      1 %


      34 %


      13 %













      Segment profit












      Amount

      $                  687


      $                  531


      $                    37


      $                    18


      $                  179


      $                  118

      Growth rate

      29 %


      7 %


      106 %


      N.M.


      52 %


      11 %

      Segment profit margin

      1.13 %


      1.04 %


      1.14 %


      0.57 %


      10.38 %


      9.20 %



      Year-to-Date














      Pharmaceutical and Specialty Solutions


      Global Medical Products and Distribution


      Other

      (in millions)

      2026


      2025


      2026


      2025


      2026


      2025

      Revenue












      Amount

      $           119,874


      $             98,839


      $               6,443


      $               6,277


      $               3,365


      $               2,469

      Growth rate

      21 %


      (5) %


      3 %


      2 %


      36 %


      13 %













      Segment profit












      Amount

      $                1,354


      $               1,061


      $                    83


      $                    26


      $                  345


      $                  222

      Growth rate

      28 %


      12 %


      N.M.


      13 %


      55 %


      10 %

      Segment profit margin

      1.13 %


      1.07 %


      1.29 %


      0.41 %


      10.25 %


      8.99 %


      The sum of the components and certain computations may reflect rounding adjustments.

      Schedule 5


      Cardinal Health, Inc. and Subsidiaries

      GAAP / Non-GAAP Reconciliation1











      Net















      Earnings








      Gross




      Operating

      Earnings

      Provision

      Attributable


      Net



      Diluted



      Margin


      SG&A2


      Earnings

      Before

      for

      to Non-


      Earnings3

      Effective


      EPS 3

      (in millions, except per common share amounts)

      Gross

      Growth


      Growth

      Operating

      Growth

      Income

      Income

      controlling

      Net

      Growth

      Tax

      Diluted

      Growth

      Margin

      Rate

      SG&A2

      Rate

      Earnings

      Rate

      Taxes

      Taxes

      Interests

      Earnings3

      Rate

      Rate

      EPS 3

      Rate

      Second Quarter 2026

      GAAP

      $  2,397

      23 %

      $ 1,504

      15 %

      $       707

      29 %

      $      630

      $       159

      $            (4)

      $       467

      17 %

      25.2 %

      $   1.97

      19 %

      State opioid assessments related to prior fiscal years

      —


      17


      (17)


      (17)

      (4)


      (13)



      (0.05)


      Restructuring and employee severance

      —


      —


      21


      21

      5


      16



      0.07


      Amortization and other acquisition-related costs

      —


      —


      130


      130

      20


      110



      0.46


      Acquisition-related cash & share-based compensation costs

      —


      —


      67


      67

      4


      63



      0.27


      Impairments and (gain)/loss on disposal of assets, net

      —


      —


      (14)


      (14)

      (3)


      (11)



      (0.06)


      Litigation (recoveries)/charges, net

      —


      —


      (18)


      (18)

      (8)


      (10)



      (0.04)


      Non-GAAP

      $  2,398

      24 %

      $ 1,520

      16 %

      $       877

      38 %

      $      799

      $       171

      $            (4)

      $       624

      33 %

      21.4 %

      $   2.63

      36 %



      Second Quarter 2025

      GAAP

      $  1,941

      5 %

      $ 1,306

      3 %

      $       549

      9 %

      $      511

      $       110

      $            (1)

      $       400

      9 %

      21.4 %

      $   1.65

      10 %

      Restructuring and employee severance

      —


      —


      9


      9

      2


      7



      0.03


      Amortization and other acquisition-related costs

      —


      —


      105


      105

      27


      78



      0.32


      Impairments and (gain)/loss on disposal of assets, net

      —


      —


      3


      3

      1


      2



      0.01


      Litigation (recoveries)/charges, net

      —


      —


      (31)


      (31)

      (12)


      (19)



      (0.08)


      Non-GAAP

      $  1,941

      5 %

      $ 1,306

      3 %

      $       635

      9 %

      $      597

      $       127

      $            (1)

      $       468

      1 %

      21.4 %

      $   1.93

      2 %


      1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules. 

      2 Distribution, selling, general and administrative expenses.  

      3 Attributable to Cardinal Health, Inc. 

      The sum of the components and certain computations may reflect rounding adjustments. 

      We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred. 

      Schedule 5


      Cardinal Health, Inc. and Subsidiaries

      GAAP / Non-GAAP Reconciliation1











      Net















      Earnings








      Gross




      Operating

      Earnings

      Provision

      Attributable


      Net



      Diluted



      Margin


      SG&A2


      Earnings

      Before

       for

      to Non-


      Earnings3

      Effective


      EPS 3

      (in millions, except per common share amounts)

      Gross

      Growth


      Growth

      Operating

      Growth

      Income

      Income

      controlling

      Net

      Growth

      Tax

      Diluted

      Growth

      Margin

      Rate

      SG&A2

      Rate

      Earnings

      Rate

      Taxes

      Taxes

      Interests

      Earnings3

      Rate

      Rate

      EPS 3

      Rate

      Year-to-Date 2026

      GAAP

      $ 4,716

      23 %

      $ 2,965

      15 %

      $     1,375

      23 %

      $    1,228

      $       303

      $            (8)

      $       917

      12 %

      24.7 %

      $   3.85

      15 %

      State opioid assessments related to prior fiscal years

      —


      17


      (17)


      (17)

      (4)


      (13)



      (0.05)


      Restructuring and employee severance

      —


      —


      41


      41

      9


      32



      0.13


      Amortization and other acquisition-related costs

      —


      —


      234


      234

      49


      185



      0.78


      Acquisition-related cash & share-based compensation costs

      —


      —


      131


      131

      5


      126



      0.53


      Impairments and (gain)/loss on disposal of assets, net

      —


      —


      (12)


      (12)

      (3)


      (9)



      (0.03)


      Litigation (recoveries)/charges, net

      —


      —


      (18)


      (18)

      (14)


      (4)



      (0.02)


      Non-GAAP

      $ 4,716

      23 %

      $ 2,982

      15 %

      $     1,734

      38 %

      $    1,587

      $       344

      $            (8)

      $     1,235

      33 %

      21.7 %

      $   5.18

      36 %

















      Year-to-Date 2025

      GAAP

      $ 3,843

      7 %

      $ 2,583

      5 %

      $     1,117

      N.M.

      $    1,052

      $       234

      $            (2)

      $       816

      N.M.

      22.2 %

      $   3.35

      N.M.

      Restructuring and employee severance

      —


      —


      33


      33

      8


      25



      0.10


      Amortization and other acquisition-related costs

      —


      —


      179


      179

      47


      132



      0.54


      Impairments and (gain)/loss on disposal of assets, net

      —


      —


      2


      2

      —


      2



      0.01


      Litigation (recoveries)/charges, net

      —


      —


      (71)


      (71)

      (24)


      (47)



      (0.19)


      Non-GAAP

      $ 3,843

      7 %

      $ 2,583

      5 %

      $     1,260

      10 %

      $    1,195

      $       266

      $            (2)

      $       927

      4 %

      22.2 %

      $   3.81

      6 %


      1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules. 

      2 Distribution, selling, general and administrative expenses.  

      3 Attributable to Cardinal Health, Inc. 

      The sum of the components and certain computations may reflect rounding adjustments. 

      We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred. 

      Schedule 6


      Cardinal Health, Inc. and Subsidiaries

      GAAP / Non-GAAP Reconciliation - GAAP Cash Flow to Non-GAAP Adjusted Free Cash Flow










      Second Quarter


      Year-to-Date

      (in millions)

      2026


      2025


      2026


      2025

      GAAP - Cash Flow Categories








      Net cash provided by/(used in) operating activities

      $               686


      $              (396)


      $             1,659


      $            (2,043)

      Net cash used in investing activities

      (1,980)


      (976)


      (2,122)


      (1,064)

      Net cash provided by/(used in) financing activities

      (519)


      2,327


      (629)


      1,787

      Effect of exchange rates changes on cash and equivalents

      (3)


      (12)


      (5)


      (3)

      Net increase/(decrease) in cash and equivalents

      $           (1,816)


      $               943


      $            (1,097)


      $            (1,323)









      Non-GAAP Adjusted Free Cash Flow








      Net cash provided by/(used in) operating activities

      $               686


      $              (396)


      $             1,659


      $            (2,043)

      Repurchases of liability-classified Specialty Alliance Units

      6


      —


      22


      —

      Additions to property and equipment

      (131)


      (99)


      (239)


      (189)

      Payments related to matters included in litigation (recoveries)/charges, net

      (18)


      245


      386


      621

      Non-GAAP Adjusted Free Cash Flow

      $               543


      $              (250)


      $             1,828


      $            (1,611)


      For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules. 

      Cardinal Health, Inc. and Subsidiaries

      Use of Non-GAAP Measures
      This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP").

      In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. 

      Exclusions from Non-GAAP Financial Measures
      Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors' assessment of the business for the reasons identified below:

      • LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies' financial results. We did not recognize any LIFO charges or credits during the periods presented.
      • State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.
      • Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance, and realigning operations.
      • Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets and amortization as a result of basis differences in equity method investments are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current, and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity's initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity, and size of acquisitions.
      • Acquisition-related cash and share-based compensation costs are incurred in connection with contingent cash payments or the issuance of share-based payment awards, which include service requirements, as a part of certain physician practice acquisitions. These costs include fair value adjustments for liability-classified awards. These costs are excluded because they are unrelated to the underlying operating results of our business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. In addition, the magnitude of these expenses is significantly impacted by the timing and size of the acquisitions of physician practices.
      • Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current, and forecasted financial results.
      • Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.

      The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. 

      Non-GAAP adjusted free cash flow: We provide this non-GAAP financial measure as a supplemental metric to assist readers in assessing the effects of items and events on our cash flow on a year-over-year basis and in comparing our performance to that of our peer group companies. In calculating this non-GAAP metric, certain items are excluded from net cash provided by operating activities because they relate to significant and unusual or non-recurring events and are inherently unpredictable in timing and amount. We believe adjusted free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, debt repayments, dividend payments, share repurchases, strategic acquisitions, or other strategic uses of cash. A reconciliation of our GAAP financial results to Non-GAAP adjusted free cash flow is provided in Schedule 6 of the financial statement tables included with this release.

      Forward Looking Non-GAAP Measures
      In this document, the Company presents certain forward-looking non-GAAP metrics. The Company does not provide outlook on a GAAP basis because the items that the Company excludes from GAAP to calculate the comparable non-GAAP measure can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company's routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.

      The occurrence, timing and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the Company's fiscal 2026 GAAP results. Over the past five fiscal years, the excluded items have impacted the Company's EPS from $1.79 to $8.44, which includes a $6.97 charge related to the goodwill impairment charge for the GMPD segment in fiscal 2022.

      Definitions

      Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.

      Interest and Other, net: other (income)/expense, net plus interest expense, net.

      Segment Profit: segment revenue minus (segment cost of products sold and segment distribution, selling, general and administrative expenses).

      Segment Profit margin: segment profit divided by segment revenue. 

      Non-GAAP gross margin: gross margin, excluding LIFO charges/(credits).

      Non-GAAP distribution, selling, general and administrative expenses or Non-GAAP SG&A: distribution, selling, general and administrative expenses, excluding state opioid assessment related to prior fiscal years and shareholder cooperation agreement costs.

      Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.  

      Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.

      Non-GAAP net earnings attributable to non-controlling interests: net earnings attributable to non-controlling interests excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.

      Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.

      Non-GAAP effective tax rate: provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, divided by (earnings before income taxes adjusted for the items above).

      Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. 

      Non-GAAP adjusted free cash flow: net cash provided by operating activities plus repurchases of liability-classified Specialty Alliance Units, less payments related to additions to property and equipment, excluding settlement payments and receipts related to matters included in litigation (recoveries)/charges, net, as defined above, or other significant and unusual or non-recurring cash payments or receipts.

      SOURCE Cardinal Health, Inc.

      Modal title

      Also from this source

      Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook

      Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook

      Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2027 revenues of $67.5 billion, an increase of 5% from the first quarter of...

      Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5

      Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5

      Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2027 on November 5, prior to the opening of trading...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.